Implementation of QbD in Lyophilisation – GSK, Takeda, Boehringer-Ingelheim and Baxter Sciences explain how at Lyophilisation Europe 2015
Posted: 8 April 2015 | SMi Group
SMi Group are thrilled to present the 3rd annual European event: Lyophilisation Europe, taking place on 29th & 30th June 2015, in Central London…
SMi Group are thrilled to present the 3rd annual European event: Lyophilisation Europe, taking place on 29th & 30th June 2015, in Central London.
With the rising risk of contamination and the need for improved formulation methods of biological products, robust capabilities in lyophilisation and freeze drying methods have become critical for prolonging drug life span whilst maintaining its functionality and preventing it from damage.
Innovation and efficiency is requested at every level making SMi’s 3rd annual European conference on Lyophilisation, the perfect platform to strengthen knowledge in key principles such as PAT and QbD.
Day 1 will focus on quality by design principles and modelling process development, while Day 2 explores process analytical technologies and product quality.
A keynote presentation on the implementation of QbD in Lyophilisation by Yves Mayeresse, Director of Primary and Secondary Expertise from GSK, will be just one of the event highlights this year when the show returns to London. The spotlight session on QbD will also include case studies from Takeda, Boehringer-Ingelheim and Baxter Sciences, with topics such as risk assessment, process improvement, drug stability, scale up and ICH guidelines being discussed.
Further information and a brochure is available online at www.lyophilisationconference.com
For those who are interested in attending there is currently a £200 early bird discount which expires on 30th April.
29 – 30 June 2015
Holiday Inn Regents Park Hotel, London, UK